Yang Yanlong, Hu Zaoxiu, Sun Hongwen, Yu Qinghe, Yang Linzhu, Yin Fang, Sun Yongmen, Pu Lisha, Zhu Xingming, Li Shen, Chen Xiaobo, Zhao Yunping
Department of Thoracic Surgery, The First Affiliated Hospital of Kunming Medical University, Kunming, 650032, People's Republic of China.
Department of Pathology, The Third Affiliated Hospital of Kunming Medical University (Yunnan Cancer Hospital, Yunnan Cancer Center), Kunming, 650118, People's Republic of China.
Onco Targets Ther. 2021 Dec 24;14:5477-5492. doi: 10.2147/OTT.S325203. eCollection 2021.
Lung adenocarcinoma (LUAD) is a major type of NSCLC and has high morbidity and mortality. The identification of useful prognostic biomarkers for LUAD is important. CBX7 has been reported in various cancers yet its expression level and potential roles have not been fully understood.
GEPIA, Oncomine, TCGA, KM plotter and OSluca databases were used to explore the expression profile and prognostic effects of CBX7 mRNA expression in patients with LUAD. TIMER was used to explore the relationship between CBX7 and immune infiltrating cells. GSEA was used to further explore the potential biological process and pathways regulated by CBX7 in LUAD. Lastly, IHC detection of CBX7 in 95 samples was used to validate the result.
We found CBX7 was downregulated in LUAD in GEPIA, Oncomine and TCGA databases. TCGA, KM plotter and OSluca databases suggested that CBX7 was associated with poor clinical outcomes and low survival rate. Using TIMER, we found that CBX7 might be associated with immune infiltration. Via gene set enrichment analysis, we found that tumor-associated biological processes and signaling pathways were enriched in the CBX7 downregulated group. Using clinical samples, we found that CBX7 protein has low expression in LUAD and was associated with poor survival.
CBX7 might serve as a promising biomarker and potential molecular target in LUAD.
肺腺癌（LUAD）是NSCLC的主要类型，发病率和死亡率高。识别LUAD有用的预后生物标志物很重要。CBX7已在多种癌症中报道，但其表达水平和潜在作用尚未完全了解。
使用GEPIA、Oncomine、TCGA、KM plotter和OSluca数据库探讨CBX7 mRNA表达在LUAD患者中的表达谱和预后影响。使用TIMER探讨CBX7与免疫浸润细胞之间的关系。使用GSEA进一步探讨CBX7在LUAD中调节的潜在生物学过程和途径。最后，对95个样本进行CBX7的免疫组化检测以验证结果。
我们发现CBX7在GEPIA、Oncomine和TCGA数据库中的LUAD中表达下调。TCGA、KM plotter和OSluca数据库表明CBX7与不良临床结局和低生存率相关。使用TIMER，我们发现CBX7可能与免疫浸润有关。通过基因集富集分析，我们发现在CBX7下调组中肿瘤相关生物学过程和信号通路富集。使用临床样本，我们发现CBX7蛋白在LUAD中低表达且与不良生存相关。
CBX7可能是LUAD中有前景的生物标志物和潜在分子靶点。
